These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 15081562

  • 1. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK, Whitaker DA, Sobel BE, Schneider DJ.
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [Abstract] [Full Text] [Related]

  • 2. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 3. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
    Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD.
    Circulation; 2001 Sep 18; 104(12):1374-9. PubMed ID: 11560852
    [Abstract] [Full Text] [Related]

  • 4. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
    Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, Michelson AD.
    J Am Coll Cardiol; 2004 Jun 16; 43(12):2319-25. PubMed ID: 15193700
    [Abstract] [Full Text] [Related]

  • 5. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 16; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 6. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 7. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
    Hamilton SF, Miller MW, Thompson CA, Dale GL.
    J Lab Clin Med; 2004 May 14; 143(5):320-6. PubMed ID: 15122176
    [Abstract] [Full Text] [Related]

  • 8. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 May 14; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L, Alves VL, Phillips DR.
    Circulation; 2003 Mar 04; 107(8):1123-8. PubMed ID: 12615789
    [Abstract] [Full Text] [Related]

  • 10. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM, Buckland RJ, Holgate CE, Storey RF.
    Platelets; 2005 Nov 04; 16(7):398-407. PubMed ID: 16236601
    [Abstract] [Full Text] [Related]

  • 11. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C.
    Blood; 1998 Nov 01; 92(9):3240-9. PubMed ID: 9787160
    [Abstract] [Full Text] [Related]

  • 12. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B.
    J Pharmacol Exp Ther; 1998 Jun 01; 285(3):1317-26. PubMed ID: 9618439
    [Abstract] [Full Text] [Related]

  • 13. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2003 Feb 01; 145(2):e6. PubMed ID: 12595861
    [Abstract] [Full Text] [Related]

  • 14. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S, Clutton P, Varghese S, Cox D, Mascelli MA, Freedman JE.
    Thromb Res; 2004 Feb 01; 113(3-4):225-33. PubMed ID: 15140587
    [Abstract] [Full Text] [Related]

  • 15. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV, Khaspekova SG, Zabotina AM, Shimanova YV, Mazurov AV.
    Platelets; 2007 Nov 01; 18(7):506-14. PubMed ID: 17957566
    [Abstract] [Full Text] [Related]

  • 16. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 01; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 17. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M, Pergolini P, Camaro C, Restifo M, Rolla R, Schaffer A, Di Giovine G, Marino P, Bellomo G, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS).
    Blood Coagul Fibrinolysis; 2013 Jun 01; 24(4):411-8. PubMed ID: 23412353
    [Abstract] [Full Text] [Related]

  • 18. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A, Wendel HP, Azevedo R, Ziemer G.
    Eur J Cardiothorac Surg; 2005 Apr 01; 27(4):617-21. PubMed ID: 15784360
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
    Li Y, Spencer FA, Ball S, Becker RC.
    J Thromb Thrombolysis; 2000 Aug 01; 10(1):69-76. PubMed ID: 10947916
    [Abstract] [Full Text] [Related]

  • 20. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
    Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE.
    Thromb Haemost; 2001 Feb 01; 85(2):309-13. PubMed ID: 11246553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.